Toward optimizing pomalidomide therapy in MM patients

Klaus Podar

doi:10.1182/blood-2015-05-641746

Toward optimizing pomalidomide therapy in MM patients

Klaus Podar

Research output: Journal article (peer-reviewed) › Journal article

1 Citation (Scopus)

Abstract

In this issue of Blood, Sehgal et al report on the clinical and pharmacodynamic analysis of pomalidomide dosing strategies in multiple myeloma (MM) and their impact on immune activation and cereblon targets. The particular novelty of this study lies in the direct correlation of immune effects triggered by pomalidomide with clinical responses in MM patients. Results of this study will stimulate many additional studies.

Original language	English
Pages (from-to)	3968-3969
Number of pages	2
Journal	Blood
Volume	125
Issue number	26
DOIs	https://doi.org/10.1182/blood-2015-05-641746
Publication status	Published - 25 Jun 2015
Externally published	Yes

Keywords

Angiogenesis Inhibitors/therapeutic use
Female
Humans
Male
Multiple Myeloma/drug therapy
Thalidomide/analogs & derivatives

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood-2015-05-641746

Cite this

@article{d908b1ec5e0a42c4b15a6a7beb25cc5b,

title = "Toward optimizing pomalidomide therapy in MM patients",

abstract = "In this issue of Blood, Sehgal et al report on the clinical and pharmacodynamic analysis of pomalidomide dosing strategies in multiple myeloma (MM) and their impact on immune activation and cereblon targets. The particular novelty of this study lies in the direct correlation of immune effects triggered by pomalidomide with clinical responses in MM patients. Results of this study will stimulate many additional studies.",

keywords = "Angiogenesis Inhibitors/therapeutic use, Female, Humans, Male, Multiple Myeloma/drug therapy, Thalidomide/analogs & derivatives",

author = "Klaus Podar",

note = "Publisher Copyright: {\textcopyright} 2015 by The American Society of Hematology.",

year = "2015",

month = jun,

day = "25",

doi = "10.1182/blood-2015-05-641746",

language = "English",

volume = "125",

pages = "3968--3969",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier B.V.",

number = "26",

}

TY - JOUR

T1 - Toward optimizing pomalidomide therapy in MM patients

AU - Podar, Klaus

PY - 2015/6/25

Y1 - 2015/6/25

N2 - In this issue of Blood, Sehgal et al report on the clinical and pharmacodynamic analysis of pomalidomide dosing strategies in multiple myeloma (MM) and their impact on immune activation and cereblon targets. The particular novelty of this study lies in the direct correlation of immune effects triggered by pomalidomide with clinical responses in MM patients. Results of this study will stimulate many additional studies.

AB - In this issue of Blood, Sehgal et al report on the clinical and pharmacodynamic analysis of pomalidomide dosing strategies in multiple myeloma (MM) and their impact on immune activation and cereblon targets. The particular novelty of this study lies in the direct correlation of immune effects triggered by pomalidomide with clinical responses in MM patients. Results of this study will stimulate many additional studies.

KW - Angiogenesis Inhibitors/therapeutic use

KW - Female

KW - Humans

KW - Male

KW - Multiple Myeloma/drug therapy

KW - Thalidomide/analogs & derivatives

UR - http://www.scopus.com/inward/record.url?scp=84933575811&partnerID=8YFLogxK

U2 - 10.1182/blood-2015-05-641746

DO - 10.1182/blood-2015-05-641746

M3 - Journal article

C2 - 26113530

SN - 0006-4971

VL - 125

SP - 3968

EP - 3969

JO - Blood

JF - Blood

IS - 26

ER -

Toward optimizing pomalidomide therapy in MM patients

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this